
Purpose of the Fund Procurement
(Head office: Shinjuku-ku, Tokyo; President: Toshiharu Furukawa) was established on January 6, 2020 as a venture from the Department of Neurosurgery, Faculty of Medicine, Keio University, with the aim of commercializing gene cell therapy methods for intractable brain diseases using genome-edited iPS cells. iXgene, Inc.
The company had been developing a brain tumor treatment using iPS cell-derived neural stem cells with a suicide gene introduced by genome editing, and has now provided a total of 600 million yen in Series A financing.
The funds raised will be used to advance non-clinical trials for brain tumor therapeutic applications and to develop genome-edited iPS-derived neural stem cells for first-in-human use.
Keio Innovation Initiative Inc. is the lead investor in this allocation, which also includes the University of Tokyo Collaborative Platform Development Corporation, MSF Capital Partners LLC, a CVC of H.U. Group Holdings, Inc. and Greencore Corporation.
List of investors in this round (*in no particular order)
Keio Innovation Initiative, Inc.
The University of Tokyo Collaborative Platform Development Corporation (Head Office: Bunkyo-ku, Tokyo; Representative Director: Katsuhiko Oizumi)
MSF Capital Partners LLC (Head office: Shinjuku-ku, Tokyo; Naoki Kitamura, Executive Director)
Greencore Corporation (Head office: Shibuya-ku, Tokyo; Representative Director: Ryusuke Honjo)
Comments from Toshiharu Furukawa, President of iXgene, Inc.
Our mission is to develop platform technologies for the treatment of various intractable diseases for which there are no established treatments, by combining iPS cell and gene editing technologies. The company aims to develop regenerative medicine for traumatic brain injury and cerebral infarction using genome-edited neural stem cells. Through this fundraising, we are now in a position to expect business support in addition to financial support for the start of corporate clinical trials in the next few years. We will do our utmost to provide our treatment method to patients as soon as possible.
Comment from Mr. Yukatsu Hongo, Keio Innovation Initiative
iXgene is tackling the extremely challenging theme of providing new treatments for malignant brain tumors, an area of high unmet medical need, using independently developed genome-edited iPS cell-derived neural stem cells. The fact that the company is able to tackle such a difficult theme because it is a medical school start-up, and the fact that it has a strong team of management and science founders working on the business, were also points that were highly evaluated when we decided to invest in the company. We are very pleased to welcome new investors through this capital increase and look forward to working together with them to take on this challenge. We will continue to make every effort to contribute to the company's future growth.
About iXgene Corporation

| name of company | iXgene Corporation |
| Establishment | January 6, 2020 |
| Location | 204, La Atre Shinjuku-Gyoen, 1-6 Naito-cho, Shinjuku-ku, Tokyo |
| representative | Representative Director Toshiharu Furukawa |
| Business Overview | Development of a treatment for intractable brain diseases using genome-edited iPS cells |
| uniform resouce locator | http://www.ixgene.inc |









